Physician profile
Gregory S Paniccia
NPI 1518022920
$20,516.55
in general payments reported to CMS, 2019-2025
29 companies · $4,908 in 2025
The $4,908 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $2,255 · 2021: $2,367 · 2022: $2,572 · 2023: $3,438 · 2024: $3,068 · 2025: $4,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,300.23 |
| Education | $114.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,895.21 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $2,241.46 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $2,179.87 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,962.89 | 2019-2025 | Ingrezza |
| Abbvie INC. | $1,906.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,600.40 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,482.39 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $1,283.56 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $1,200.02 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $1,198.84 | 2019-2022 | |
| Indivior INC. | $658.55 | 2019-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $444.58 | 2024-2025 | Cobenfy |
| Allergan, INC. | $412.79 | 2019-2020 | |
| Axsome Therapeutics, INC. | $262.64 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $147.06 | 2022-2024 | Trintellix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $119.53 | 2023-2024 | Quviviq |
| Livanova USA, INC. | $83.19 | 2022-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Neuronetics, INC. | $79.05 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $74.09 | 2024-2025 | Nuplazid |
| Noven Therapeutics, LLC | $49.48 | 2020-2021 | |
| Corium, LLC | $49.31 | 2021-2023 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.21 | 2022 | |
| Ironshore Pharmaceuticals INC. | $33.40 | 2019 | |
| Biogen, INC. | $24.37 | 2024 | |
| Vertical Pharmaceuticals, LLC | $19.25 | 2019 | |
| Noven Pharmaceuticals, INC. | $17.25 | 2021 | |
| Eisai INC. | $16.96 | 2020 | |
| Almatica Pharma LLC | $14.99 | 2025 | Loreev Xr |
| Tempus Ai, INC | $13.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Paniccia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.